113 related articles for article (PubMed ID: 30203024)
1. Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients.
Facchin A; Bui S; Leroux S; Nacka F; Koehl B; Maksoud E; Fayon M; Jacqz-Aigrain E;
J Antimicrob Chemother; 2018 Dec; 73(12):3423-3429. PubMed ID: 30203024
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.
Maksoud E; Koehl B; Facchin A; Ha P; Zhao W; Kaguelidou F; Benkerrou M; Mariani P; Faye A; Lorrot M; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378711
[TBL] [Abstract][Full Text] [Related]
3. Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation.
Thuo N; Ungphakorn W; Karisa J; Muchohi S; Muturi A; Kokwaro G; Thomson AH; Maitland K
J Antimicrob Chemother; 2011 Oct; 66(10):2336-45. PubMed ID: 21831986
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.
Hirt D; Oualha M; Pasquiers B; Blanot S; Rubinstazjn R; Glorion C; Messaoudi SE; Drummond D; Lopez V; Toubiana J; Béranger A; Boujaafar S; Zheng Y; Capito C; Winter S; Léger PL; Berthaud R; Gana I; Foissac F; Tréluyer JM; Bouazza N; Benaboud S
Eur J Clin Pharmacol; 2021 Nov; 77(11):1687-1695. PubMed ID: 34160669
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
6. Defining optimal dosing of ciprofloxacin in patients with septic shock.
Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
11. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
[TBL] [Abstract][Full Text] [Related]
12. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats.
Iqbal Z; Javed I; Basit A; Jan I; Khan AA
Pak J Pharm Sci; 2011 Jan; 24(1):69-74. PubMed ID: 21190922
[TBL] [Abstract][Full Text] [Related]
14. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
Pea F; Poz D; Viale P; Pavan F; Furlanut M
J Antimicrob Chemother; 2006 Aug; 58(2):380-6. PubMed ID: 16735422
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin Pharmacokinetics in Clinical Canine Patients.
Papich MG
J Vet Intern Med; 2017 Sep; 31(5):1508-1513. PubMed ID: 28771831
[TBL] [Abstract][Full Text] [Related]
18. Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.
Meesters K; Michelet R; Mauel R; Raes A; Van Bocxlaer J; Vande Walle J; Vermeulen A
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987142
[TBL] [Abstract][Full Text] [Related]
19. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.
Haeseker M; Stolk L; Nieman F; Hoebe C; Neef C; Bruggeman C; Verbon A
Br J Clin Pharmacol; 2013 Jan; 75(1):180-5. PubMed ID: 22616681
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
